SEARCH

SEARCH BY CITATION

Keywords:

  • Synaptic transmission;
  • Epilepsy;
  • Presynaptic;
  • Postsynaptic;
  • Neuropeptides;
  • Synaptic vesciles;
  • Antiepileptic drugs

Summary

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

Synaptic transmission is the communication between a presynaptic and a postsynaptic neuron, and the subsequent processing of the signal. These processes are complex and highly regulated, reflecting their importance in normal brain functioning and homeostasis. Sustaining synaptic transmission depends on the continuing cycle of synaptic vesicle formation, release, and endocytosis, which requires proteins such as dynamin, syndapin, synapsin, and synaptic vesicle protein 2A. Synaptic transmission is regulated by diverse mechanisms, including presynaptic modulators of synaptic vesicle formation and release, postsynaptic receptors and signaling, and modulators of neurotransmission. Neurotransmitters released presynaptically can bind to their postsynaptic receptors, the inhibitory γ-aminobutyric acid (GABA)ergic receptors or the excitatory glutamate receptors. Once released, glutamate activates a variety of postsynaptic receptors including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA), kainate, and metabotropic receptors. The activation of the receptors triggers downstream signaling cascades generating a vast array of effects, which can be modulated by a numerous auxiliary regulatory subunits. Moreover, different neuropeptides such as neuropeptide Y, brain-derived neurotrophic factor (BDNF), somatostatin, ghrelin, and galanin, act as regulators of diverse synaptic functions and along with the classic neurotransmitters. Abnormalities in the regulation of synaptic transmission play a critical role in the pathogenesis of numerous brain diseases, including epilepsy. This review focuses on the different mechanisms involved in the regulation of synaptic transmission, which may play a role in the pathogenesis of epilepsy: the presynaptic modulators of synaptic vesicle formation and release, postsynaptic receptors, and modulators of neurotransmission, including the mechanism by which drugs can modulate the frequency and severity of epileptic seizures.

Synaptic transmission is the process by which neurotransmitters released from the presynaptic neuronal terminal bind to, and activate, receptors on the postsynaptic neuron, and the subsequent processing of the signal. When the neurons are communicating in a healthy brain, an appropriated integration of sensory input and a balance between excitatory and inhibitory systems in response to a stimulus, gives the individual the ability to generate appropriate responses that meet the demands of the environment. Reflecting its importance to brain functioning, the processes of synaptic neurotransmission are tightly regulated, including the proteins involved in synaptic vesicle formation, neurotransmitter release and subsequent vesicle endocytosis and recycling, neurotransmitter reuptake, the effects of the neurotransmitter itself on postsynaptic receptors, and subsequent signaling cascades and modulation of the signal communicated through the synapse. In addition, auxiliary subunits interact with the receptor-ligand complexes to modulate their properties. Furthermore, certain small proteins, such as trophins, hormones, and other peptides, can regulate the characteristics of the synaptic signal. All these diverse presynaptic, synaptic, and postsynaptic elements elegantly regulate the communication between neurons in the multiple and complex neuronal networks that make up the brain.

Abnormalities in the regulation of synaptic transmission play a role in the pathogenesis of many brain diseases. A consequence of this is a disruption to the equilibrium between excitation and inhibition in neuronal networks, which can lead to inappropriate neuronal firing and ultimately the generation of spontaneous, recurrent seizures. The spread of inappropriate neuronal firing to other neurons in the network is normally prevented by surrounding regulatory and modulatory synaptic mechanisms. This article reviews the different aspects of the regulation of synaptic transmission that may play a role in the pathogenesis of epilepsy, and how drugs can utilize these mechanisms to reduce the frequency and severity of epileptic seizures in people with epilepsy. Figure 1 summarizes the different proteins/regulatory subunits that are discussed and Table 1 defines the abbreviations used through the article.

image

Figure 1.  Schematic illustration of different elements involved in regulation of synaptic transmission. The arrows represent the path a synaptic vesicle follows from endocytosis to exocytosis. 1*, syndapin and dynamin are key proteins that modulate the synaptic vesicle endocytosis by pinching off the budding membrane into a synaptic vesicle ready to be filled by neurotransmitters. 2*, vesicular glutamate transporter (VGLUT) and vesicular GABA transporter (VGAT) help to fill the synaptic vesicle with the neurotransmitters glutamate and GABA, respectively. Synapsin I and II and SV2A are key proteins that modulate the synaptic vesicle exocytosis. 3*, the postsynaptic receptors include the ionotropic glutamate receptors, AMPA, NMDA, and kainate receptors. The seven transmembrane G-protein–coupled metabotropic receptor, mGluR, can be found both presynaptically and postsynaptically. The G protein is composed of α, β, and γ subunits. In addition, auxiliary subunits, like the TARPs, CNIH, Neto, DREAM, and Homer can interact with the receptor-ligand complexes to modulate their properties. 4*, the neuropeptides regulate the characteristics of the synaptic signal, with receptors that are located either presynaptically or postsynaptically. The receptors for ghrelin, somatostatin, NPY, and galanin are G-protein coupled. TrkB activation by BDNF causes phosphorylation of CREB and Egr3 to regulate NMDA and GABA receptor synthesis.

Download figure to PowerPoint

Table 1.   Abbreviations used in the article
AbbreviationMeaning
ABPAMPA-receptor binding protein
ADAR2Adenosine deaminase acting on RNA
AgRPAgouti-related protein
AMPAα-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ATPAdenosine triphosphate
BDNFBrain-derived neurotrophic factor
Ca2+Calcium
CaMKIICa2+/calmodulin-dependent protein kinase II
cAMPCyclic adenosine monophosphate
CKAMP44Cystine-knot AMPAR modulating protein
CNIHCornichon
CNSCentral nervous system
CP-AMPACalcium permeable AMPA receptors
CREBcAMP response element binding protein
DGDentate gyrus
DREAMDownstream regulatory element antagonist modulator
EEGElectroencephalography
Egr3Early growth response factor 3
EPSCsExcitatory postsynaptic currents
EREndoplasmic reticulum
GABAγ-Aminobutyric acid
GAERSGenetic absence epilepsy rats from Strasbourg
GalRGalanin receptor
GHSRGrowth hormone secretagogue receptor
GRIPGlutamate receptor interacting protein
iGluRIonotropic glutamate receptor
IPSCsInhibitory postsynaptic currents
K+Potassium
KARKainate receptors
LTDLong-term depression
LTPLong-term potentiation
MAPKMitogen-activated protein kinase
mGluRMetabotropic glutamate receptors
mRNAMessenger ribonucleic acid
Na+Sodium
NMDA N-methyl-d-aspartate
NPYNeuropeptide Y
nRTReticular thalamic nucleus
PDZZonula occludens
PICK1Protein interacting with C-kinase 1
PKCProtein kinase C
PPPancreatic polypeptide
PSDPostsynaptic density
PSD-95Postsynaptic density-95
PTZPentylenetetrazol
PYYPeptide YY
SAP-97Synapse-associated protein of 97 kDa
SEStatus epilepticus
SNAP-23Synaptosomal-associated protein 23
SOL-1Suppressor of lurcher
SV2ASynaptic vesicle protein 2A
SYNSynapsin
SynDIG1Synapse differentially induced gene 1
SYPSynaptophysin
TARPTransmembrane AMPA receptor regulatory protein
TLETemporal lobe epilepsy
TrkBReceptor tyrosine protein kinase B
VGATVesicular GABA transporter
VGCCVoltage-gated calcium channels
VGLUTVesicular glutamate transporter
WAG/RijWistar Albino Glaxo Rats from Rijswijk

Modulators of Synaptic Vesicle Formation, Release, and Recycling

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

Sustaining synaptic transmission depends upon the cycle of formation, release, and reformation of synaptic vesicles via membrane recycling processes of exocytosis and endocytosis (Heine, 2012). Multiple proteins are involved in these processes, such as synapsin, dynamin, syndapin, and synaptic vesicle proteins. Long-term changes in presynaptic morphology and synaptic vesicle recycling at hippocampal mossy fiber CA3 terminals of rats and mice after pilocarpine-induced status epilepticus (SE) have been described. The changes include alterations in the morphology of mossy fiber synaptic buttons, including increased size, number of release sites, and number of vesicles in the reserve pool and the readily releasable pool. These changes suggest that the morphologic changes are components of the response to increased activation that underlie enhanced transmitter release (Upreti et al., 2012). In agreement Goussakov et al. (2000) found an increase in glutamate release from the readily releasable pool and loss of paired-pulse facilitation, a presynaptic short term mechanism of synaptic plasticity, in the kainic acid model of temporal lobe epilepsy (TLE). In addition, number of active zones (characterized by synaptic vesicles in proximity to a presynaptic density, widening of the synaptic cleft, and asymmetry between presynaptic and postsynaptic densities), increased action potential–driven vesicular release, and enhanced vesicle endocytosis have been documented at the mossy fiber synaptic button in models of pilocarpine-induced SE, which persisted at least 1 month (Upreti et al., 2012). However, of the numerous proteins involved in vesicle release and recycling systems, only a few have to date been related directly to epileptogenesis, including synaptic vesicle protein 2A (SV2A), synapsin, dynamin, and syndapins (Qualmann et al., 1999; van Vliet et al., 2009; Raimondi et al., 2011).

Synaptic vesicle protein 2A

SV2A is the most abundant and widely expressed member of a family of membrane-bound glycoproteins found on synaptic vesicles. This family is encoded by three different genes: SV2A, SV2B, and SV2C (Janz & Sudhof, 1999; Janz et al., 1999). SV2A is the only member of the family expressed in γ-aminobutyric acid (GABA)ergic neurons (Bajjalieh et al., 1994), and has become of particular interest to the epilepsy field since it was discovered to be the target of binding of the antiepileptic drug levetiracetam (Lynch et al., 2004).

SV2A plays a role as a regulator of synaptic vesicle exocytosis and influences the calcium (Ca2+) homeostasis of synaptic vesicle constituents by regulating the expression and trafficking of the Ca2+-binding protein synaptotagmin (Yao et al., 2010), and influencing the presynaptic Ca2+ and adenosine triphosphate (ATP) concentrations (Janz et al., 1999; Yao & Bajjalieh, 2008; Wan et al., 2010). Studies on SV2A knockout mice have shown reduced evoked action potential–dependent transmitter release from inhibitory neurons (Custer et al., 2006; Chang & Sudhof, 2009). In addition, mice in which the function of both SV2A and SV2B has been knocked out showed an increase in Ca2+-dependent synaptic transmission (Janz et al., 1999). This led to the hypothesis that SV2A can regulate presynaptic Ca2+ release, and that the dysfunction of this protein could lead to Ca2+ accumulation during repeated action potential generation, ultimately resulting in increased neurotransmitter release and destabilization of neuronal circuits, facilitated by excitatory transmission and a concurrent attenuation of inhibition (Janz et al., 1999). SV2A expression is decreased throughout the hippocampus of patients with drug-resistant TLE with hippocampal sclerosis (van Vliet et al., 2009). Similarly, SV2A has been found to be decreased throughout the hippocampus of epileptic rats, particularly in the mossy fiber terminals in the latent and chronic epileptic phase post-SE (van Vliet et al., 2009). These data support the hypothesis that reduced expression of SV2A contributes to an increased epileptogenicity.

Drugs interacting with synaptic vesicle protein 2A

Levetiracetam has arguably been the most successful of the new-generation antiepileptic drugs introduced into clinical practice over the last two decades, with broad spectrum efficacy against a range of focal and generalized seizure types (De Smedt et al., 2007; Lo et al., 2011). Levetiracetam has a novel mechanism of action relative to that of the older antiepileptic drugs, in that it binds with high affinity to SV2A (Lynch et al., 2004) and inhibits presynaptic Ca2+ channels (Vogl et al., 2012). However, the exact mechanism by which levetiracetam inhibits seizures remains to be determined (Kaminski et al., 2009). Novel levetiracetam analogs, brivaracetam and seletracetam, also bind to SV2A (Bennett et al., 2007; von Rosenstiel, 2007). Both brivaracetam and seletracetam bind more potently to the SV2A than levetiracetam, and there is some evidence for superior efficacy in preclinical models (Matagne et al., 2009). However, it is uncertain whether this will translate into improved clinical effectiveness.

Synapsins

The synapsins are phosphoproteins that are highly expressed in presynaptic boutons, where they interact with small synaptic vesicles to regulate neuronal development, neurotransmission, and plasticity (Bogen et al., 2011). There are three different synapsin proteins: synapsin I (SynI), synapsin II (SynII), and synapsin III (SynIII). In general, SynI and SynII are more abundant in hippocampal and cortical excitatory synapses than in inhibitory synapses (Kielland et al., 2006). The synapsins have direct involvement in the regulation of synaptic vesicle dynamics. They control synaptic vesicle trafficking between the reserve pool and the readily releasable pool in a phosphorylation-dependent fashion (Chi et al., 2003; Baldelli et al., 2007; Messa et al., 2010). Synapsin binds the synaptic vesicle to the cytoskeleton, which prevents them from being trafficked to the presynaptic membrane. During an action potential, synapsins are phosphorylated by Ca2+/calmodulin–dependent protein kinase II (CaMKII), releasing the synaptic vesicles and allowing them to move to the presynaptic terminal and release neurotransmitter. Moreover, synapsins play a role in the final post-docking steps of exocytosis, including synaptic vesicle priming and fusion to the synaptic membrane (Hilfiker et al., 2005; Chiappalone et al., 2009). Knockout mice models of SynI, SynII, SynI/II, and SynI/II/III manifest an epileptic phenotype, indicating that synaptic vesicle cycling plays an important role in epileptogenesis (Etholm et al., 2011, 2012; Farisello et al., 2012). The different effects in these knockout models are complex and not fully understood. Of interest, the seizure phenotype varies depending on which isoform has been deleted. However, in general, the loss of synapsins disrupts the reserve pool of synaptic vesicles and enhances synaptic depression, which is seen more markedly in glutamatergic than in GABAergic synapses. This can result in an imbalance between synaptic excitatory and inhibitory transmission, both under conditions of basal electrical activity and of high-frequency stimulation, potentially leading to a hyperexcitable seizure-prone state (Farisello et al., 2012).

In humans, a missense mutation in the gene coding for SynI has been found as a cause of different epilepsy phenotypes in a four-generational family, with some affected members also having aggressive behavior, learning disabilities, or autism (Garcia et al., 2004). Recently, another missense mutation in the human SYN1 gene was identified in all affected individuals from a large French–Canadian family with epilepsy and autism spectrum disorders (Fassio et al., 2011). In addition, population genetic studies have identified single nucleotide polymorphisms in the human SYN2 gene that show an association with epilepsy in certain populations (Cavalleri et al., 2007; Lakhan et al., 2010).

Dynamin

The dynamins are a family of proteins with GTPase activity that are involved in endocytic vesicle formation. After the plasma membrane invaginates at the beginning of vesicular endocytosis, dynamin forms a helix that expands and twists around the neck of the new budding vesicle. As this process continues, dynamin tweaks the budding membrane into a synaptic vesicle, ready to be filled by neurotransmitters (Ramachandran, 2011). There are three subtypes of dynamin, each with different expression profiles. Dynamin 1 is expressed in the brain, with highest expression in the cortex, amygdala, striatum, and neuroendocrine cells (Faire et al., 1992). Dynamin 2 is expressed in most cell types in the body, including the brain. Dynamin 3 is highly expressed in the testis and also in the brain, heart, and lung (Cao et al., 1998; Ferguson & De Camilli, 2012).

At least two pathways by which dynamin regulates vesicle endocytosis have been identified: a quick, high capacity pathway that acts during intense neuronal activity, mediated by dynamin 1, and a low capacity pathway that is suppressed during stimulation but is gradually activated when stimulation ceases, mediated by dynamin 2 (Ferguson et al., 2007). Dynamin 1 becomes active only when an intense stimulus imposes a heavy burden on endocytosis and only as long as the stimulus persists. In dynamin 1 knockout mice, dynamin 3 is recruited into the synapses in a compensatory fashion; however, since its expression is much lower, dynamin 3 cannot cope with the demands imposed at high neuronal activity, resulting in decreased synaptic transmission efficiency (Ferguson et al., 2007).

Although there is currently no direct evidence linking the dynamin proteins to epilepsy in humans, a missense mutation in dynamin 1 has recently been found to cause the epilepsy phenotype in the “fitful” mouse model (Boumil et al., 2010). Dynamin-associated mechanisms have been suggested as a possible target for novel antiepileptic drugs, as it has been shown that inhibiting dynamin binding to syndapin with a peptide-based inhibitor produced an activity-dependent rundown in synaptic transmission. The peptide had no effect on synaptic transmission for 45 s, but after this delay it became progressively more inhibited, suggesting that this approach may be able to selectively inhibit the sustained neuronal firing that occurs during a seizure while allowing physiologic neurotransmission to occur normally (Anggono et al., 2006). The search for new drugs for epilepsy targeting endocytosis and other mechanisms associated with synaptic vesicle recycling is underway. There are ongoing pre-studies testing dynamin drugs in rodent models of seizures and epilepsy, including in our group, with proof of concept efficacy being demonstrated. The potential attractiveness of this approach is that the targeting of synaptic vesicle recycling may have selective effects to inhibit sustained neuronal firing, as occurs in a seizure that is highly dependent on synaptic vesicle endocytosis, while allowing normal physiologic neuronal firing to continue unaffected (Anggono et al., 2006).

Syndapin

Syndapins (Synaptic dynamin-associated proteins) are highly conserved Src-homology 3-domain–containing proteins. They interact with dynamin and several other vesicular trafficking proteins involved in vesicular endocytosis (Qualmann et al., 1999; Qualmann & Kelly, 2000). Mice that lack syndapin I show impairments in synaptic vesicle formation and synaptic transmission (Koch et al., 2011). The alterations in synaptic vesicle formation are explained by the close interplay between syndapin and dynamin (Ferguson et al., 2007). The syndapins bind to the three isoforms of dynamin, and in syndapin I knockout mice, the recruitment of dynamin was impaired (Koch et al., 2011). The alterations seen in synaptic vesicle size and endocytic mechanisms mimic those seen in the dynamin knockout mice models (Ferguson et al., 2007; Koch et al., 2011). Reduced evoked excitatory postsynaptic current (EPSC) and inhibitory postsynaptic current (IPSC) amplitudes, and the stronger impairment of IPSCs, were especially shown with very high frequency stimulation in knockout syndapin mice (Andersson et al., 2008). Taken together, these defects led to an increased hippocampal network activity with lowered threshold for epileptiform discharges, strongly increased amplitudes of epileptiform discharges, as well as a much higher power of induced gamma oscillations, which in turn may lead to the generation of seizures (Clayton et al., 2009; Koch et al., 2011). In humans, syndapin I is found in the gene locus 6p21.3, which has been reported to be associated with genetic generalized epilepsy (Turnbull et al., 2005).

Postsynaptic Receptor Regulation

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

Neurotransmitters released presynaptically can bind to their postsynaptic receptors and activate downstream signaling cascades, the effects of which can be modulated by a vast array of auxiliary regulatory subunits. Regulators of postsynaptic neurotransmission ionotropic glutamate receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA], N-methyl-d-aspartate [NMDA], and kainate receptors) and metabotropic glutamate receptors are discussed. The role of GABA receptors in the regulation of synaptic transmission is discussed in other articles in this supplement.

Glutamate receptors

The major excitatory neurotransmitter in the brain is glutamate. Glutamate receptors can be divided into two major groups based on the mechanism by which their activation gives rise to the postsynaptic currents: ionotropic and metabotropic, with several subtypes existing for each group. Due the vast array of different subtypes of glutamate receptors, a wide range of physiologic processes are regulated by these receptors. Excessive glutamate receptor activation has been linked to a number of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and schizophrenia, in addition to epilepsy (Sheldon & Robinson, 2007). Recent work has shed light on another level of modulation of glutamate receptors by regulatory proteins.

Ionotropic glutamate receptors

The ionotropic glutamate receptor (iGluR) family is divided into four distinct subgroups based on receptor pharmacology and structural homology, including the AMPA receptors (GluA1–GluA4), kainate receptors (GluK1–GluK5), NMDA receptors (GluN1, GluN2A–GluN2D, GluN3A, and GluN3B), and δ receptors (GluD1 and GluD2) (Dingledine et al., 1999). The iGluRs are tetramers with a binding site for glutamate on each subunit that assemble as dimer of dimers, and their composition can be homomeric or heteromeric (Traynelis et al., 2010).

AMPA receptors.  The majority of fast excitatory synaptic neurotransmission in the central nervous system (CNS) is mediated by glutamate activation of AMPA receptors (Dingledine et al., 1999). In addition to initiating neuronal firing, AMPA receptors also underlie aspects of synaptic plasticity (Dingledine et al., 1999), such as such as long-term potentiation (LTP) (Selcher et al., 2012). AMPA receptors are tetrameric assemblies of GluA1 to GluA4 subunits (Traynelis et al., 2010). Although homomeric receptors are functional, native AMPA receptors are believed to be heteromers. For example, in hippocampal pyramidal cells of mature rats, the most common subunit configurations are GluA1/GluA2 and GluA2/GluA3 (Dingledine et al., 1999; Traynelis et al., 2010). The permeability to Ca2+ ions of AMPA receptors is governed by the GluA2 subunit. The presence of a GluA2 subunit renders the channel impermeable to Ca2+ due to the posttranslational mRNA editing of a glutamine (Q) to an arginine (R) residue (Seeburg & Hartner, 2003). The majority of GluA2 subunits in the CNS are edited to the GluA2(R) form, thus the principal ions gated by these AMPA receptors are sodium (Na+) and potassium (K+) (Dingledine et al., 1999). Conversely, AMPA receptors lacking GluA2- or containing an unedited (Q form) of GluA2 are rendered permeable to Ca2+ ions (Sommer et al., 1991). This editing is catalyzed by the enzyme adenosine deaminase acting on RNA (ADAR2). This enzyme has also shown to edit the Kv1.1 potassium channel, conferring a loss in 4-aminopyridine sensitivity to kainic acid–induced seizures (Streit et al., 2011). The imbalance between AMPA receptors and CP-AMPA receptors has been related to epileptogenesis (Tanaka et al., 2000), the processes by which a normal brain becomes epileptic (McNamara et al., 2006). Krestel et al. (2004) showed in adult rat brains that seizure susceptibility is increased by the presence of the CP-AMPAR (GluA2[Q] receptors), and that these types of receptors play a role in circuit hyperexcitability. In addition, susceptibility to hypoxia-induced seizures occurs in the brain during developmental stages when there is an increased expression of CP-AMPA receptors. Consequently, perinatal hypoxia-induced seizures increase the expression of CP-AMPA receptors and the capacity for an AMPA receptor–mediated epileptogenesis (Sanchez et al., 2001). Moreover, studies have found a reduction in the GluA2 subunit in the amygdala, piriform cortex, and limbic forebrain in rats after amygdala kindling (Prince et al., 1995, 2000). Furthermore, decreased mRNA expression of GluA2 was found in the hippocampal CA1 region and dentate gyrus in rats experiencing pentylenetetrazol (PTZ) –induced seizures (Ekonomou et al., 2001). In the pilocarpine model of TLE, increased levels of CP-AMPAR were observed in the hippocampal membrane, which can contribute to the elevation of intracellular Ca2+ during recurrent burst firing. In addition, AMPAR–mediated currents became inwardly rectifying in the hippocampal CA1 neurons and dentate granule cells (Rajasekaran et al., 2012). Moreover, the R/G editing, another posttranslational modification, of the GluA2 subunit was found to be increased in the hippocampus and temporal cortex from patients with refractory epilepsy. The increased editing at the R/G site in the hippocampal tissue of epilepsy patients may enhance responses to glutamate (Vollmar et al., 2004). Furthermore, a mutation in the Gria4 gene, which codes for the GluA4 subunit, has been identified in C3H/HeJ mice, which exhibit spontaneous absence seizures (Beyer et al., 2008). This mutation results in decreased expression of GluA4, which is one of the main AMPA-receptor subunits expressed in the reticular thalamic nucleus (nRT), and the predominant subunit in corticothalamic neurons (Mineff & Weinberg, 2000). GluA4-containing receptors have the fastest desensitization rate to glutamate (Mosbacher et al., 1994). Therefore, reduced expression of GluA4 can increase the duration of response to excitatory input by glutamate. This event could in turn promote increased burst firing in reticular neurons enhancing circuit synchrony (Meeren et al., 2002).

AMPA receptors can interact with a variety of proteins in the postsynaptic membrane that function as auxiliary subunits and can modify their properties. The majority of these interactions occur through the cytoplasmic C-terminal tail of AMPA receptors, with proteins containing postsynaptic density-95 (PSD-95), discs large, zonula occludens (PDZ) domains, including glutamate receptor interacting protein (GRIP), AMPA-receptor binding protein (ABP), protein interacting with C-kinase 1 (PICK1), and synapse-associated protein of 97 kDa (SAP-97), or via non-PDZ domains (Srivastava et al., 1998; Dev et al., 1999; Kim & Huganir, 1999; Xia et al., 1999). Proteins that contain a PDZ domain that have been shown to interact with AMPA receptors include the transmembrane AMPA receptor regulatory proteins (TARPs; Chen et al., 2000), cornichon homologs (CNIH-2, CNIH-3; Schwenk et al., 2009), synapse differentially induced gene 1 (SynDIG1; Kalashnikova et al., 2010), and cystine-knot AMPAR-modulating protein (CKAMP44; von Engelhardt et al., 2010). These proteins differentially regulate AMPA-receptor channel gating and are involved in subunit folding, assembly, surface expression, and clustering and anchoring of AMPA receptors at synapses (Diaz, 2010; Jackson & Nicoll, 2011).

Transmembrane AMPA receptor regulatory proteins: TARPs are a family of proteins— including stargazin (γ2), γ3, γ 4, γ5, γ7, and γ8—with distinct and complementary expression patterns in both neurons and glia in the developing and mature CNS (Tomita et al., 2003; Kato et al., 2010). Stargazin (γ2) was the first TARP identified when a mutation in its gene (Cacng2) was found to cause the stargazer mouse, which manifests spontaneous absence-like seizures with generalized spike-and-wave discharges as well as having cerebellar ataxia (Letts et al., 1998). Stargazin was found to have structural homology to the γ1 subunit of the skeletal muscle voltage-gated Ca2+ channels (VGCCs) (Letts et al., 1998). Structurally, TARPs comprise four transmembrane domains and cytosolic amino- and carboxy-termini containing the PDZ domain. Despite the structural similarity with γ1, the TARPS are not expressed on the skeletal muscle and have minor or no effect on VGCCs (Tomita et al., 2003; Fukaya et al., 2005).

The TARPs regulate many different characteristics of the AMPA receptors such as AMPAR biogenesis, trafficking, anchoring AMPARs at the synapse, as well as modulating the channel kinetics. In the endoplasmic reticulum (ER), AMPA receptors are assembled by the formation of dimers and tetramers. TARPs associate with the tetrameric AMPAR to act as an auxiliary subunit permitting the efficient export of the AMPAR from the ER to the Golgi. Then, nPIST (a Golgi-enriched protein involved with trafficking of transmembrane proteins) binds to the C-terminal tail of stargazin in Golgi and assists the AMPAR–TARP complex to exit the Golgi and traffic it to the cell surface (Chen et al., 2000; Ziff, 2007). The AMPAR-TARP complex diffuses into the postsynaptic density PSD, where PSD-95 binds to the PDZ domain of the C-terminal tail of the TARP to anchor the complex at the synapse (Choi et al., 2002; Tomita et al., 2003, 2004; Ziff, 2007). Phosphorylation of TARPs by protein kinase C (PKC) and CaMKII is important in mediating AMPA-receptor synaptic transmission (Inamura et al., 2006). For example, stargazin phosphorylation increases AMPA-receptor synaptic trafficking, thereby establishing stargazin as critical in controlling synaptic strength (Tomita et al., 2005). Furthermore, TARPs can modify synaptic plasticity by affecting AMPA-receptor biophysical properties such as reduced receptor desensitization, slowed receptor deactivation rates, and increased recovery for desensitization (Priel et al., 2005).

Stargazer mice, which harbor a mutation in the stargazin gene that results in a decrease in expression of the stargazin protein, lack functional AMPA receptors in the cerebellum (Letts et al., 1998). In the thalamocortical synapses, AMPA receptors are reduced in the nRT, due to a reduction of GluA4 and GluA2/3 subunit expression (Barad et al., 2012). In contrast, the levels of AMPA receptors in the cortex remain unchanged, probably because stargazin is not the predominant TARP expressed in the cerebral cortex and the possible compensatory effect of the other TARPs expressed in the cortex (Tomita et al., 2003; Fukaya et al., 2005). In the Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a model of genetic generalized epilepsy that manifests spontaneous absence seizures associated with generalized spike-and-wave discharges on electroencephalography (EEG), without any other neurologic deficit, stargazin expression is increased in the somatosensory cortex and thalamus (Powell et al., 2008). This increase in stargazin expression was also associated with an increase in the cortical membrane expression of AMPA-receptor subunits GluA1 and GluA2 (Kennard et al., 2011). The findings in these two rodent models illustrate that either a decrease or an increase in stargazin expression can be associated with an absence seizures phenotype, highlighting that perturbations in AMPA-mediated synaptic transmission, either positively or negatively, can result in an epileptic network.

Drugs that modulate AMPA receptors: Drugs that can inhibit AMPA-receptor activity have the potential to reduce excessive excitatory responses and may be promising future antiepileptic drugs (Meldrum & Rogawski, 2007; Rogawski, 2011). Perampanel, a noncompetitive and highly selective AMPA-receptor antagonist, is currently in phase III development as an adjunctive treatment for drug-resistant partial-onset seizures (Krauss et al., 2012). Parampanel also decreases intracellular Ca2+ concentration induced by AMPA-receptor activation, which would have the net effect of decreasing excitability (Hanada et al., 2011; Ceolin et al., 2012). Perampanel has been shown to have antiseizure effects in a broad range of rodent models, but showed no effect in the GAERS model, suggesting that it is less likely to be effective clinically against absence seizures (Hanada et al., 2011).

N-methyl-d-aspartate receptors.  NMDA receptors play a crucial role in excitatory neurotransmission regulation in the CNS. NMDA receptors are cationic channels permeable to Na+, K+, and Ca2+ (Perez-Otano & Ehlers, 2005). The Ca2+ influx through NMDA receptors is the critical factor that mediates many of its roles in health and disease (Cull-Candy & Leszkiewicz, 2004). The NMDA receptors are tetramers composed of different subunits: GluN1, GluN2A–GluN2D, and GluN3A–GluN3B (Traynelis et al., 2010). GluN1 is a necessary subunit of all NMDARs; genetic deletion of this subunit causes death in neonatal stages (Forrest et al., 1994). The C-terminus region of GluN1 regulates NMDAR trafficking and binding to proteins, including calmodulin, CaMKII, yotiao, alpha-actinin, tubulin, neurofilaments, and downstream regulatory element antagonist modulator (DREAM; Cull-Candy & Leszkiewicz, 2004; Horak & Wenthold, 2009).

Both GluN2A and GluN2B subunits are highly expressed in the cortex and hippocampus, where they are reported to control synaptic plasticity and metaplasticity (Monyer et al., 1994). Mutations in the GRIN2A gene, which codes for the human GluN2A, have been identified in patients with idiopathic epilepsy (Endele et al., 2010). Moreover, haplotypes of GRIN1, the gene encoding for the human GluN1 subunit, have been associated with infantile spasms, further indicating an involvement of NMDARs in epilepsy (Ding et al., 2010). Decreased GluN2B mRNA expression has been found in pyramidal neurons of TLE patients with hippocampal sclerosis, whereas an up-regulation of this subunit was found in pyramidal cells of nonsclerotic hippocampi from epileptic patients (Mathern et al., 1998).

Drugs that alter NMDA receptor properties: Felbamate was the first new-generation antiepileptic drug introduced in the 1990s, and it is highly effective against a broad range of seizure types (Sachdeo et al., 1992), but has had its clinical use severely limited following the discovery that it rarely results in the potential fatal adverse effects of aplastic anemia and liver failure (Pellock, 1999). Felbamate inhibits NMDA-evoked responses, preferentially in NMDA receptors containing GluN2B subunits, as well as potentiates GABA-evoked responses (Sofia, 1994).

Remacemide is a low-affinity noncompetitive antagonist of NMDA receptors (Subramaniam et al., 1996; Norris & King, 1997) but has also been shown to inhibit sustained repetitive firing in cultured neurons by blocking voltage-activated Na+ channels (Garske et al., 1991). Remacemide is effective against a broad range of animal seizure models (Palmer et al., 1991). However, clinical trials of remacemide have overall shown relatively disappointing efficacy (Cramer et al., 1994; Brodie et al., 2002; Wesnes et al., 2009). Other potential new antiepileptic drugs in development that have been found to have effects in at least part by modulating NMDA-receptor action include losigamone (Srinivasan et al., 1997), which also reduces potassium-evoked release of glutamate and aspartate from cortical slices (Draguhn et al., 1997) and enhances GABAergic synaptic transmission (Dimpfel et al., 1995). Huperzine A, which shows protective activity against partial seizures in animal models (Schneider et al., 2009), is an NMDA-receptor antagonist (Zhang et al., 2002) and can reduce glutamate-induced toxicity (Ved et al., 1997).

Kainate receptors.  Kainate receptors (KARs) are members of the iGluR receptor family that show distinctive characteristics. Unlike AMPA and NMDA receptors, KARs are not predominantly found in excitatory postsynaptic complexes (Contractor & Swanson, 2008). Instead, KARs act as modulators of synaptic transmission and neuronal excitability. Noticeably, they link to metabotropic (G-protein–mediated) signaling pathways in addition to operating as ionotropic receptors (Rodriguez-Moreno & Lerma, 1998). KARs are distributed throughout the brain pre- and postsynaptically and are involved in the regulation of activity of synaptic networks by postsynaptic depolarization at a subset of excitatory synapses, in presynaptic regulation of neurotransmitter release, in presynaptic modulation of both excitatory and inhibitory transmission, in refinement of synaptic strength during development, and in enhancement of neuronal excitability (Contractor et al., 2011). The KARs are tetramers formed by combinations of low-affinity, GluK1–GluK3, and high affinity, GluK4–GluK5 subunits (Collingridge et al., 2009). All subunits contribute to the formation of the ionic pore and each one contains a glutamate-binding site (Fisher & Mott, 2011).

It is notable that in a rat model of TLE, aberrant synaptic kainite receptors dramatically expand the temporal window for synaptic integration in dentate granular cells. This introduces a change in the input–output operation of dentate granule cell that switches their firing from a sparse to an abnormal sustained and rhythmic mode (Artinian et al., 2011). Moreover, in the entorhinal cortex, both GluK1 and GluK2 have been implicated in regulating the network oscillations and enhancing both glutamate and GABA release in this critical area for epileptogenesis in mesial TLE (Bartolomei et al., 2005; Chamberlain et al., 2012).

Drugs that modulate kainate receptors: There are no antiepileptic drugs in clinical practice, or in advanced clinical development, that have been shown to have effects primarily on kainate receptors. However, the experimental compound, LY293558, which inhibits GluK1-containing kainate receptors, has been shown to be effective in reducing the duration of SE in rats (Figueiredo et al., 2011). This drug is a nonselective antagonist, having effects on kainate and AMPA receptors (Alt et al., 2006; Jane et al., 2009).

Metabotropic glutamate receptors

The family of metabotropic glutamate receptors (mGluRs) are composed of eight receptor subtypes, grouped into three different families according to their amino acid homology, pharmacologic properties, and G-protein coupling (Conn & Pin, 1997). In general, the mGluRs are found preferentially in presynaptic terminals, where they negatively regulate neurotransmitter release (Ferraguti & Shigemoto, 2006). The exception are the group I mGluRs, which are found predominantly in the periphery of the postsynaptic density, where they generate excitatory responses and regulate mechanisms of synaptic plasticity (Ferraguti et al., 2008). Group I mGlu1Rs, can be activated with repetitive high-frequency stimulation of corticothalamic afferents (Turner & Salt, 2000; Hughes et al., 2002). When activated, these receptors can modulate the excitability of thalamic relay cells in the relay nuclei (Turner & Salt, 1998; Alexander & Godwin, 2006a; Alexander et al., 2006). In the Wistar Albino Glaxo Rats from Rijswijk (WAG/Rij) rat model of genetic generalized epilepsy that exhibits spontaneous absence seizures, a reduction of mGlu1-receptor expression in the thalamus was correlated with seizure expression (Ngomba et al., 2011). Younger WAG/Rij rats that are not having absence seizures did not show reduction in mGlu1-receptor expression of spike and wave discharges. In addition, activation of mGlu1 receptors by agonists confers a protective effect against the development of seizures (Ngomba et al., 2011). In contrast, the group II mGluRs modulate the inhibitory circuitry of the thalamus via a GABAergic mechanism. This inhibition occurs in the thalamic relay cells, both presynaptically and postsynaptically (Salt & Eaton, 1995; Salt & Turner, 1998; Turner & Salt, 2003). Furthermore, the activation of the group II mGluRs can cause presynaptic inhibition of the corticothalamic input onto the cells of the relay and nRT of the thalamus, potentially reducing the excitatory cortical drive onto GABAergic cells (Turner & Salt, 2003; Alexander & Godwin, 2005). Activation of the group III of mGluRs has been shown to reduce GABAergic inhibitory responses within the thalamus by inhibiting the corticothalamic input onto thalamic relay cells, mediated by activation of mGlu7 and mGlu8 receptors (Turner & Salt, 2003; Kogo et al., 2004).

Metabotropic glutamate receptors regulatory proteins.  Homer proteins (Homer 1, 2, and 3) are a family of scaffolding proteins found to regulate mGluR 1 and mGluR5 function and to facilitate coupling to effectors such as the inositol triphosphate receptor (Shin et al., 2003; Klugmann et al., 2005; Kammermeier & Worley, 2007) they are also found to be up-regulated in various CNS disorders including epilepsy (Potschka et al., 2002). Of interest, expression of Homer1a is induced during intense neuronal activities like LTP, seizures, and synaptogenesis (Kato et al., 1997). In addition, expression of Homer1a is augmented in various animal models of TLE, including the pilocarpine-induced SE and amygdala kindling models (Potschka et al., 2002; Avedissian et al., 2007), and has been considered to reduce seizure susceptibility in cortical pyramidal neurons by dampening neuronal excitability (Sakagami et al., 2005).

Metabotropic glutamate receptor modulating drugs.  Subtype-selective mGluR ligands are under preclinical and early clinical development for the treatment of neurologic and psychiatric disorders, including epilepsy, in particular because of the properties of mGluR to modulate the excitability of thalamic relay cells (Alexander & Godwin, 2006b; Govindaiah & Cox, 2006). SYN119, a mGluR1 enhancer, was found to reduce spontaneous spike and wave discharges in WAG/Rij rats (Ngomba et al., 2011).

Neuropeptide Modulators of Synaptic Neurotransmission

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

The neuropeptides such as neuropeptide Y (NPY), somatostatin, ghrelin, and galanin, act as regulators of diverse synaptic functions and occur concomitantly with the classic neurotransmitters (Brain & Cox, 2006). They are short peptides of 3–100 amino acid residues long, with a less complex three-dimensional structure than proteins (Portelli et al., 2012). The majority of the neuropeptide receptors are members of the G-protein–coupled receptor family. Several neuropeptides and their receptors have been implicated in the pathogenesis of epilepsy, mostly by regulating the classical neurotransmitters systems, either by modifying the release of neurotransmitters or by regulating the effects of their activated receptors. This review will focus on the effects of systemic neuropeptide modulators rather than small molecule/peptide modulators such as adenosine (Boison, 2012; Moschovos et al., 2012).

Neuropeptide Y

NPY is a member of a neuropeptide family, which comprises NPY, peptide YY (PYY), and pancreatic polypeptide (PP) (Cabrele & Beck-Sickinger, 2000). NPY is a 36-amino acid peptide that is abundantly expressed in GABAergic interneurons of the mammalian CNS, with highest expression seen in the cerebral cortex, dentate hilus, striatum, the nRT, and the arcuate nucleus of the hypothalamus. NPY acts as a neurotransmitter that is synthesized and released by neurons (Gehlert, 1994; Pedrazzini et al., 2003). In the CNS, NPY acts to enhance inhibitory neurotransmission, and to dampen excitatory neurotransmission (Bacci et al., 2002). NPY has been shown to have antiepileptic effects in a number of models of acquired and genetic epilepsy (Cabrele & Beck-Sickinger, 2000; Tu et al., 2005; Noe et al., 2008; van Raay et al., 2012). NPY has been shown to be up-regulated in the temporal lobe from patients who have had resective surgery performed for chronic drug-resistant epilepsy (Furtinger et al., 2001), as well as in the hippocampus, dentate gyrus, and cortex from seizure/epilepsy animal models including electroshock-evoked seizures, pilocarpine-induced SE, pentylenetetrazol (PTZ)–induced seizures, kindling, and after electrically induced SE (Vezzani et al., 1996; Poulsen et al., 2002; Tu et al., 2005; Cardoso et al., 2010). Work from our group has also demonstrated that NPY has potent antiepileptic effect in the GAERS model of genetic generalized epilepsy (Stroud et al., 2005; Morris et al., 2007; van Raay et al., 2012). This suggests that NPY may act as an endogenous antiepileptic factor. Consistent with this finding, it has been shown that rats that have been injected bilaterally into the hippocampi with an adenoassociated viral vector to overexpress NPY are resistant to epileptogenesis induced by electrical kindling and SE (Richichi et al., 2004; Noe et al., 2009).

NPY signals through identified Y1, Y2, Y4, and Y5 receptors that couple to G-proteins, inhibiting adenylate cyclase and thus decreasing intracellular Ca2+ levels (Baraban, 2004; Walther et al., 2011). The receptors Y1R and Y5R bind preferentially to NPY, whereas Y4Rs have a high affinity for PP, and Y2R binds NPY and PYY with similar affinities (Cabrele & Beck-Sickinger, 2000; Guo et al., 2002; Fetissov et al., 2004; Merten & Beck-Sickinger, 2006; Lindner et al., 2008). Y1Rs are mainly expressed postsynaptically in the hippocampus, cerebral cortex, thalamus, and amygdala, and act to increase synaptic inhibition (Widdowson, 1993; Cabrele & Beck-Sickinger, 2000). Y5Rs are expressed postsynaptically in the hippocampus and hypothalamus, and like the Y1R, acts to increase synaptic inhibition (Guo et al., 2002). In contrast, Y2Rs are expressed presynaptically in the hippocampus, thalamus, hypothalamus, and cerebral cortex (Widdowson, 1993; Cabrele & Beck-Sickinger, 2000). Due to the presynaptic localization of NPY, it suppresses the release of neurotransmitters, in particular glutamate, thereby dampening excitatory neurotransmission (El Bahh et al., 2005). Studies investigating which NPY receptor subtypes are most important in mediating its antiepileptic actions have produced conflicting results, with work using models of acquired limbic epilepsy mostly implicating either Y1R or Y5R (Baraban, 1998; Marsh et al., 1999; Vezzani et al., 2000), whereas work in the GAERS model primarily implicates the Y2Rs (Morris et al., 2007).

There are many studies demonstrating the efficacy of NPY against a broad range of rodent models of both focal and generalized epilepsy when administered directly into the brain or cerebrospinal fluid (Marksteiner et al., 1989; Erickson et al., 1996; Kofler et al., 1997; Vezzani et al., 1999; Reibel et al., 2001; Noe et al., 2008, 2009; Sorensen et al., 2009). Selective NPY receptor antagonists have been developed with the aim of being new treatment for a variety of conditions including anxiety, sleep disorders, eating disorders, in addition to epilepsy (Ortiz et al., 2007; Wiater et al., 2011; Wu et al., 2011; van Raay et al., 2012). However, the barriers to clinical development have been developing compounds that are orally active, have sufficiently long half-life, and cross the blood–brain barrier (Meurs et al., 2007). One potential approach to overcome these barriers is to use viral-based gene therapy, focally administered into epileptogenic brain regions that selectively up-regulate NPY expression. Such an approach using NPY-containing adenoassociated virus vectors has shown proof-of-concept efficacy in several rat models of epilepsy (Richichi et al., 2004; Noe et al., 2008; Jovanovska et al., 2011).

Ghrelin

Ghrelin is a 28 amino acid hunger-stimulating peptide mainly produced by the neurons in the hypothalamus and by the X/A-like cells of the oxyntic stomach mucosa (Camina et al., 2003). Ghrelin plays a significant role in a variety of physiologic processes such as appetite regulation, metabolism, LTP, and cognition (Wu & Kral, 2004; Atcha et al., 2009). Ghrelin binds to the G-protein–coupled growth hormone secretagogue receptor (GHSR1a), which is expressed at high density in the hippocampus, hypothalamus, and pituitary (Camina, 2006; Portelli et al., 2012). Activation of the ghrelin receptor leads to increased activity of NPY/AgRP (agouti-related protein) neurons, presynaptic release of NPY, as well as an increased rate of GABA secretion in hypothalamic slice preparations (Cowley et al., 2003).

Studies from animal models have implicated ghrelin in epileptogenesis. Intraperitoneal injections of ghrelin delayed or prevented the development of PTZ-induced seizures in rats (Obay et al., 2007). Portelli et al. found that ghrelin release desensitizes the GHSR, and that this interaction leads to the attenuation of limbic seizures induced by pilocarpine in vivo and epileptiform activity in vitro. In contrast, another group found that ghrelin was unable to prevent seizures induced by kainic acid or pilocarpine. This group also found that des-acyl ghrelin, which accounts only for about 10% of the circulating ghrelin, can be beneficial in limbic seizures (Biagini et al., 2011). These contrasting results raise questions about the specific role of ghrelin in epilepsy and highlighted the need for further studies to address this discrepancy.

Somatostatin

Somatostatin is a neuropeptide produced by the neuroendocrine neurons of the periventricular nucleus of the hypothalamus and is involved with the regulation of the endocrine system and affects neurotransmission and cell proliferation (Viollet et al., 2008). Somatostatin binds with high affinity to G-protein–coupled somatostatin receptors, SST1, SST2A, SST2B, SST3, SST4 and SST5 (Patel, 1999). Somatostatin secreting neurons are present in a variety of brain areas, including the mediobasal hypothalamus, median eminence, amygdala, preoptic area, hippocampus, striatum, cerebral cortex, olfactory regions, and the brainstem (Epelbaum et al., 1994; Gulyas et al., 2003; Tomioka et al., 2005). The extensive expression of somatostatin throughout the brain and the large number of SST receptor subtypes allows somatostatin to affect a diverse array of physiologic functions (Viollet et al., 2008). The regulatory effects of somatostatin are mostly presynaptic by interacting with the receptors SST1, SST2, SST4, and SST5 (Baraban & Tallent, 2004). On the other hand, most of the neurotransmitter-like effects of somatostatin are mediated by activation of the SST2 receptor (Viollet et al., 2008). Changes in expression of somatostatin and its receptors in the hippocampus have been reported in a variety of animal models of epilepsy. A decrease in SST2 receptor expression in the outer molecular layer of the hippocampus was observed following repeated seizures induced by amygdala kindling and kainate animal models of TLE (Binaschi et al., 2003). Furthermore, a progressive decrease in SST2A receptors and a progressive increase in somatostatin immunoreactivity was observed in the outer molecular layer of the dentate gyrus after repeated seizures elicited by hippocampal kindling (Csaba et al., 2004). In addition, a loss of somatostatin-expressing inhibitory neurons resulting in reduced granule cell inhibition has been reported after pilocarpine-induced SE (Kobayashi & Buckmaster, 2003). A decrease in SST2 receptor immunoreactivity and mRNA expression in the CA1 and CA3 regions of the hippocampus has been reported in patients with temporal lobe epilepsy with hippocampal sclerosis, suggested to be due to neuronal loss (Csaba et al., 2005). In contrast, in the dentate gyrus, SST2 mRNA was strongly up-regulated, and SST2 binding was increased in the inner molecular layer but robustly decreased in the outer molecular layer.

Galanin

Galanin is a neuropeptide that is widely expressed throughout the brain and spinal cord and binds to three different G-protein–coupled receptors, GalR1, GalR1 and GalR3 (Mitsukawa et al., 2010). Activation of galanin receptors results in inhibition of presynaptic glutamate release, via a mechanism involving ATP-dependent K+ channels, which in turns lead to membrane hyperpolarization, a process furthermore enhanced by the additional effect of galanin to directly close VGCC (Zini et al., 1993; Mazarati et al., 2000). It is notable that galanin does not alter the inhibitory tone and has no effect on GABA release in the hippocampus (Zini et al., 1993; Mazarati & Lu, 2005). Moreover, activation of GalR2 can promote plastic reorganization in the hippocampus, and neuronal viability and survival in response to seizures (Mazarati et al., 2004). Galanin and GalR agonists have been shown to have antiseizure effects in a variety of animal models (Floren et al., 2005; Mazarati & Lu, 2005; Mazarati et al., 2006). GalR1 knockout mice exhibit spontaneous seizures and a reduced inhibition in the hippocampus (McColl et al., 2006). Whereas, GalR2 knockout mice showed no differences compared to wild-type controls in the latency to seizures induced by PTZ or flurothyl (Gottsch et al., 2005).

Saar et al. synthesized galnon, the first nonpeptide low–molecular-weight GalR1 and GalR2 agonist (Saar et al., 2002; Floren et al., 2005). Systemic administration of galnon showed potent anticonvulsant effects on PTZ-induced seizures and inhibited perforant path stimulation-induced SE in rats (Saar et al., 2002). Galmic, another GalR agonist, has also shown positive effects in PTZ-induced seizures and in SE models in rats (Bartfai et al., 2004). NAX 5055 (Gal-B2), a GalR agonist that shows high affinity for GalR1 and GalR2, has been shown to have anticonvulsant activity in three models of epilepsy including the 6-Hz seizure model, the Frings audiogenic seizure-susceptible mouse, and the corneal kindled mouse model of partial epilepsy (Bulaj et al., 2008; White et al., 2009). Moreover, in the hippocampal kindling model of TLE, NAX 5055 reduces the seizure score without affecting the afterdischarge duration (Bialer et al., 2010). In addition, the GalR2 preferred analogs, NAX 306-1 and NAX 1205-1 display activity in the 6-Hz seizure model when systematically administered (Bialer et al., 2010).

Brain-derived neurotrophic factor

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that binds with high affinity to the receptor tyrosine protein kinase B (TrkB), which is coupled to various signaling pathways including mitogen-activated protein kinase (MAPK)/PKC, phosphatidylinositol 3-kinase, and phospholipase C (Kaplan & Miller, 2000). BDNF has wide-ranging effects during development, including regulating neuronal morphology and synaptogenesis, plus it exhibits neuroprotective effects in diverse areas of the CNS (Stansfield et al., 2012). Both BDNF and TrkB have a widespread distribution in the CNS (Hofer et al., 1990). BDNF has been implicated as a potential therapeutic target for TLE. Importantly, high levels of expression are found in cell bodies and axons in areas associated with seizure susceptibility, such as hippocampus and entorhinal cortex (Wetmore et al., 1990). The involvement of BDNF in epileptogenesis is complex. In the kainic acid/pilocarpine-induced SE, kindling, PTZ, and tetanus seizure animal models, the seizures cause a prominent increase in the expression of BDNF in the brain, in particular the hippocampus (Zafra et al., 1990; Ernfors et al., 1991; Isackson et al., 1991; Humpel et al., 1993; Nibuya et al., 1995; Schmidt-Kastner et al., 1996; Liang et al., 1998). Acute administration of BDNF into the CA3 of the hippocampus, the dentate gyrus, and medial entorhinal cortex, produces neuronal hyperexcitability (Messaoudi et al., 1998; Binder et al., 2001; Kobayashi & Buckmaster, 2003). In fact, epileptogenesis has been shown to be promoted by an increase in BDNF and BDNF-mediated activation of the TrkB in the hippocampus in mice after intrahippocampal injections of kainic acid (Heinrich et al., 2011). Studies in patients with drug-resistant TLE with hippocampal sclerosis have found an increase in BDNF mRNA expression in the hippocampus compared with those without hippocampal sclerosis (Wang et al., 2011). BDNF has been reported to regulate synaptic transmission by a variety of mechanisms including increasing NMDA currents in human patients with TLE and hippocampal sclerosis and animal hippocampal slices and attenuating inhibition on GABAergic postsynaptic cells by down-regulating chloride transport (Wang et al., 2011).

Summary and Conclusions

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

Disturbances in synaptic transmission, in particular to the balance between excitatory and inhibitory synapses, play a role in the pathogenesis of seizures and epilepsy. Such disturbances can affect almost any of the many different components of synaptic transmission, including postsynaptic and presynaptic receptors and their modulators, neuropeptide modulators, and the machinery of synaptic vesicle formation, release, and recycling. The processes of synaptic transmission are also targets for therapies for epilepsy, including many antiepileptic drugs currently in use in clinical practice as well as novel therapies under development. However, the complex processes regulating synaptic transmission in health and disease are still incompletely understood. Further advancement in our understanding of these critical processes is likely to lead to identification of new targets for the development of novel treatment approaches with potential to address the considerable treatment gaps that remain for many patients with epilepsy, in particular drug-resistant epilepsies and the lack of disease-modifying therapies (Galanopoulou et al., 2012).

Acknowledgments

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

Pablo Miguel Casillas-Espinosa was funded by a Melbourne Research Scholarship and Kim Powell from a Project Grant (#628723) from the NH&MRC.

Disclosures

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References

TJO has received research support from pharmaceutical companies that market antiepileptic drugs, specifically UCB Pharma, Sanofi-Adventis, Janssen-Cilag, Novartis, and SciGen. He has served on the Medical Advisory Boards for UCB Pharma, Janssen-Cilag, and GSK, and he has received honoraria for talks from UCB Pharma, Sanofi-Adventis, and SciGen. The other authors have no conflicts to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References

  1. Top of page
  2. Summary
  3. Modulators of Synaptic Vesicle Formation, Release, and Recycling
  4. Postsynaptic Receptor Regulation
  5. Neuropeptide Modulators of Synaptic Neurotransmission
  6. Summary and Conclusions
  7. Acknowledgments
  8. Disclosures
  9. References
  • Alexander GM, Godwin DW. (2005) Presynaptic inhibition of corticothalamic feedback by metabotropic glutamate receptors. J Neurophysiol 94:163175.
  • Alexander GM, Godwin DW. (2006a) Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res 71:122.
  • Alexander GM, Godwin DW. (2006b) Unique presynaptic and postsynaptic roles of Group II metabotropic glutamate receptors in the modulation of thalamic network activity. Neuroscience 141:501513.
  • Alexander GM, Fisher TL, Godwin DW. (2006) Differential response dynamics of corticothalamic glutamatergic synapses in the lateral geniculate nucleus and thalamic reticular nucleus. Neuroscience 137:367372.
  • Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. (2006) In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology 185:240247.
  • Andersson F, Jakobsson J, Low P, Shupliakov O, Brodin L. (2008) Perturbation of syndapin/PACSIN impairs synaptic vesicle recycling evoked by intense stimulation. J Neurosci 28:39253933.
  • Anggono V, Smillie KJ, Graham ME, Valova VA, Cousin MA, Robinson PJ. (2006) Syndapin I is the phosphorylation-regulated dynamin I partner in synaptic vesicle endocytosis. Nat Neurosci 9:752760.
  • Artinian J, Peret A, Marti G, Epsztein J, Crepel V. (2011) Synaptic kainate receptors in interplay with INaP shift the sparse firing of dentate granule cells to a sustained rhythmic mode in temporal lobe epilepsy. J Neurosci 31:1081110818.
  • Atcha Z, Chen WS, Ong AB, Wong FK, Neo A, Browne ER, Witherington J, Pemberton DJ. (2009) Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology 206:415427.
  • Avedissian M, Longo BM, Jaqueta CB, Schnabel B, Paiva PB, Mello LE, Briones MR. (2007) Hippocampal gene expression analysis using the ORESTES methodology shows that homer 1a mRNA is upregulated in the acute period of the pilocarpine epilepsy model. Hippocampus 17:130136.
  • Bacci A, Huguenard JR, Prince DA. (2002) Differential modulation of synaptic transmission by neuropeptide Y in rat neocortical neurons. Proc Natl Acad Sci U S A 99:1712517130.
  • Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14:52235235.
  • Baldelli P, Fassio A, Valtorta F, Benfenati F. (2007) Lack of synapsin I reduces the readily releasable pool of synaptic vesicles at central inhibitory synapses. J Neurosci 27:1352013531.
  • Baraban SC. (1998) Neuropeptide Y and limbic seizures. Rev Neurosci 9:117128.
  • Baraban SC. (2004) Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 38:261265.
  • Baraban SC, Tallent MK. (2004) Interneuron diversity series: interneuronal neuropeptides – endogenous regulators of neuronal excitability. Trends Neurosci 27:135142.
  • Barad Z, Shevtsova O, Arbuthnott GW, Leitch B. (2012) Selective loss of AMPA receptors at corticothalamic synapses in the epileptic stargazer mouse. Neuroscience 217:1931.
  • Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, Hua XY, Yaksh T, Haberhauer G, Ceide SC, Trembleau L, Somogyi L, Krock L, Rebek J Jr. (2004) Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A 101:1047010475.
  • Bartolomei F, Khalil M, Wendling F, Sontheimer A, Regis J, Ranjeva JP, Guye M, Chauvel P. (2005) Entorhinal cortex involvement in human mesial temporal lobe epilepsy: an electrophysiologic and volumetric study. Epilepsia 46:677687.
  • Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N. (2007) Seletracetam (UCB 44212). Neurotherapeutics 4:117122.
  • Beyer B, Deleuze C, Letts VA, Mahaffey CL, Boumil RM, Lew TA, Huguenard JR, Frankel WN. (2008) Absence seizures in C3H/HeJ and knockout mice caused by mutation of the AMPA receptor subunit Gria4. Hum Mol Genet 17:17381749.
  • Biagini G, Torsello A, Marinelli C, Gualtieri F, Vezzali R, Coco S, Bresciani E, Locatelli V. (2011) Beneficial effects of desacyl-ghrelin, hexarelin and EP-80317 in models of status epilepticus. Eur J Pharmacol 670:130136.
  • Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92:89124.
  • Binaschi A, Bregola G, Simonato M. (2003) On the role of somatostatin in seizure control: clues from the hippocampus. Rev Neurosci 14:285301.
  • Binder DK, Croll SD, Gall CM, Scharfman HE. (2001) BDNF and epilepsy: too much of a good thing? Trends Neurosci 24:4753.
  • Bogen IL, Jensen V, Hvalby O, Walaas SI. (2011) Glutamatergic neurotransmission in the synapsin I and II double knock-out mouse. Semin Cell Dev Biol 22:400407.
  • Boison D. (2012) Adenosine dysfunction in epilepsy. Glia 60:12341243.
  • Boumil RM, Letts VA, Roberts MC, Lenz C, Mahaffey CL, Zhang ZW, Moser T, Frankel WN. (2010) A missense mutation in a highly conserved alternate exon of dynamin-1 causes epilepsy in fitful mice. PLoS Genet 6:e1001046.
  • Brain SD, Cox HM. (2006) Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 147(Suppl. 1):S202S211.
  • Brodie MJ, Wroe SJ, Dean AD, Holdich TA, Whitehead J, Stevens JW. (2002) Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 3:140146.
  • Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS. (2008) Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem 51:80388047.
  • Cabrele C, Beck-Sickinger AG. (2000) Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 6:97122.
  • Camina JP. (2006) Cell biology of the ghrelin receptor. J Neuroendocrinol 18:6576.
  • Camina JP, Carreira MC, Micic D, Pombo M, Kelestimur F, Dieguez C, Casanueva FF. (2003) Regulation of ghrelin secretion and action. Endocrine 22:512.
  • Cao H, Garcia F, McNiven MA. (1998) Differential distribution of dynamin isoforms in mammalian cells. Mol Biol Cell 9:25952609.
  • Cardoso A, Freitas-da-Costa P, Carvalho LS, Lukoyanov NV. (2010) Seizure-induced changes in neuropeptide Y-containing cortical neurons: potential role for seizure threshold and epileptogenesis. Epilepsy Behav 19:559567.
  • Cavalleri GL, Weale ME, Shianna KV, Singh R, Lynch JM, Grinton B, Szoeke C, Murphy K, Kinirons P, O’Rourke D, Ge D, Depondt C, Claeys KG, Pandolfo M, Gumbs C, Walley N, McNamara J, Mulley JC, Linney KN, Sheffield LJ, Radtke RA, Tate SK, Chissoe SL, Gibson RA, Hosford D, Stanton A, Graves TD, Hanna MG, Eriksson K, Kantanen AM, Kalviainen R, O’Brien TJ, Sander JW, Duncan JS, Scheffer IE, Berkovic SF, Wood NW, Doherty CP, Delanty N, Sisodiya SM, Goldstein DB. (2007) Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case–control study. Lancet Neurol 6:970980.
  • Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. (2012) A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 61:517522.
  • Chamberlain SE, Jane DE, Jones RS. (2012) Pre- and post-synaptic functions of kainate receptors at glutamate and GABA synapses in the rat entorhinal cortex. Hippocampus 22:555576.
  • Chang WP, Sudhof TC. (2009) SV2 renders primed synaptic vesicles competent for Ca2 +  -induced exocytosis. J Neurosci 29:883897.
  • Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, Bredt DS, Nicoll RA. (2000) Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408:936943.
  • Chi P, Greengard P, Ryan TA. (2003) Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron 38:6978.
  • Chiappalone M, Casagrande S, Tedesco M, Valtorta F, Baldelli P, Martinoia S, Benfenati F. (2009) Opposite changes in glutamatergic and GABAergic transmission underlie the diffuse hyperexcitability of synapsin I-deficient cortical networks. Cereb Cortex 19:14221439.
  • Choi J, Ko J, Park E, Lee JR, Yoon J, Lim S, Kim E. (2002) Phosphorylation of stargazin by protein kinase A regulates its interaction with PSD-95. J Biol Chem 277:1235912363.
  • Clayton EL, Anggono V, Smillie KJ, Chau N, Robinson PJ, Cousin MA. (2009) The phospho-dependent dynamin-syndapin interaction triggers activity-dependent bulk endocytosis of synaptic vesicles. J Neurosci 29:77067717.
  • Collingridge GL, Olsen RW, Peters J, Spedding M. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology 56:25.
  • Conn PJ, Pin JP. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205237.
  • Contractor A, Swanson GT. (2008) Kainate receptors. In Gereau RW, Swanson GT (Eds) The glutamate receptors. Humana Press, Totowa, NJ, pp. 99158.
  • Contractor A, Mulle C, Swanson GT. (2011) Kainate receptors coming of age: milestones of two decades of research. Trends Neurosci 34:154163.
  • Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL. (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649661.
  • Cramer CL, Stagnitto ML, Knowles MA, Palmer GC. (1994) Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci 54:PL271PL275.
  • Csaba Z, Richichi C, Bernard V, Epelbaum J, Vezzani A, Dournaud P. (2004) Plasticity of somatostatin and somatostatin sst2A receptors in the rat dentate gyrus during kindling epileptogenesis. Eur J Neurosci 19:25312538.
  • Csaba Z, Pirker S, Lelouvier B, Simon A, Videau C, Epelbaum J, Czech T, Baumgartner C, Sperk G, Dournaud P. (2005) Somatostatin receptor type 2 undergoes plastic changes in the human epileptic dentate gyrus. J Neuropathol Exp Neurol 64:956969.
  • Cull-Candy SG, Leszkiewicz DN. (2004) Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004:re16.
  • Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26:13031313.
  • De Smedt T, Raedt R, Vonck K, Boon P. (2007) Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13:5778.
  • Dev KK, Nishimune A, Henley JM, Nakanishi S. (1999) The protein kinase C alpha binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits. Neuropharmacology 38:635644.
  • Diaz E. (2010) Regulation of AMPA receptors by transmembrane accessory proteins. Eur J Neurosci 32:261268.
  • Dimpfel W, Chatterjee SS, Noldner M, Ticku MK. (1995) Effects of the anticonvulsant losigamone and its isomers on the GABAA receptor system. Epilepsia 36:983989.
  • Ding YX, Zhang Y, He B, Yue WH, Zhang D, Zou LP. (2010) A possible association of responsiveness to adrenocorticotropic hormone with specific GRIN1 haplotypes in infantile spasms. Dev Med Child Neurol 52:10281032.
  • Dingledine R, Borges K, Bowie D, Traynelis SF. (1999) The glutamate receptor ion channels. Pharmacol Rev 51:761.
  • Draguhn A, Jungclaus M, Sokolowa S, Heinemann U. (1997) Losigamone decreases spontaneous synaptic activity in cultured hippocampal neurons. Eur J Pharmacol 325:245251.
  • Ekonomou A, Smith AL, Angelatou F. (2001) Changes in AMPA receptor binding and subunit messenger RNA expression in hippocampus and cortex in the pentylenetetrazole-induced ‘kindling’ model of epilepsy. Brain Res Mol Brain Res 95:2735.
  • El Bahh B, Balosso S, Hamilton T, Herzog H, Beck-Sickinger AG, Sperk G, Gehlert DR, Vezzani A, Colmers WF. (2005) The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur J Neurosci 22:14171430.
  • Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, Milh M, Kortum F, Fritsch A, Pientka FK, Hellenbroich Y, Kalscheuer VM, Kohlhase J, Moog U, Rappold G, Rauch A, Ropers HH, von Spiczak S, Tonnies H, Villeneuve N, Villard L, Zabel B, Zenker M, Laube B, Reis A, Wieczorek D, Van Maldergem L, Kutsche K. (2010) Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 42:10211026.
  • Epelbaum J, Dournaud P, Fodor M, Viollet C. (1994) The neurobiology of somatostatin. Crit Rev Neurobiol 8:2544.
  • Erickson JC, Clegg KE, Palmiter RD. (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381:415421.
  • Ernfors P, Bengzon J, Kokaia Z, Persson H, Lindvall O. (1991) Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. Neuron 7:165176.
  • Etholm L, Linden H, Eken T, Heggelund P. (2011) Electroencephalographic characterization of seizure activity in the synapsin I/II double knockout mouse. Brain Res 1383:270288.
  • Etholm L, Bahonjic E, Walaas SI, Kao HT, Heggelund P. (2012) Neuroethologically delineated differences in the seizure behavior of Synapsin 1 and Synapsin 2 knock-out mice. Epilepsy Res 99:252259.
  • Faire K, Trent F, Tepper JM, Bonder EM. (1992) Analysis of dynamin isoforms in mammalian brain: dynamin-1 expression is spatially and temporally regulated during postnatal development. Proc Natl Acad Sci U S A 89:83768380.
  • Farisello P, Boido D, Nieus T, Medrihan L, Cesca F, Valtorta F, Baldelli P, Benfenati F. (2012) Synaptic and extrasynaptic origin of the excitation/inhibition imbalance in the hippocampus of synapsin I/II/III knockout mice. Cereb Cortex Feb 24:[Epub ahead of print].
  • Fassio A, Patry L, Congia S, Onofri F, Piton A, Gauthier J, Pozzi D, Messa M, Defranchi E, Fadda M, Corradi A, Baldelli P, Lapointe L, St-Onge J, Meloche C, Mottron L, Valtorta F, Khoa Nguyen D, Rouleau GA, Benfenati F, Cossette P. (2011) SYN1 loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function. Hum Mol Genet 20:22972307.
  • Ferguson SM, De Camilli P. (2012) Dynamin, a membrane-remodelling GTPase. Nat Rev Mol Cell Biol 13:7588.
  • Ferguson SM, Brasnjo G, Hayashi M, Wolfel M, Collesi C, Giovedi S, Raimondi A, Gong LW, Ariel P, Paradise S, O’Toole E, Flavell R, Cremona O, Miesenbock G, Ryan TA, De Camilli P. (2007) A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science 316:570574.
  • Ferraguti F, Shigemoto R. (2006) Metabotropic glutamate receptors. Cell Tissue Res 326:483504.
  • Ferraguti F, Crepaldi L, Nicoletti F. (2008) Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev 60:536581.
  • Fetissov SO, Kopp J, Hokfelt T. (2004) Distribution of NPY receptors in the hypothalamus. Neuropeptides 38:175188.
  • Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF. (2011) The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther 336:303312.
  • Fisher JL, Mott DD. (2011) Distinct functional roles of subunits within the heteromeric kainate receptor. J Neurosci 31:1711317122.
  • Floren A, Sollenberg U, Lundstrom L, Zorko M, Stojan J, Budihna M, Wheatley M, Martin NP, Kilk K, Mazarati A, Bartfai T, Lindgren M, Langel U. (2005) Multiple interaction sites of galnon trigger its biological effects. Neuropeptides 39:547558.
  • Forrest D, Yuzaki M, Soares HD, Ng L, Luk DC, Sheng M, Stewart CL, Morgan JI, Connor JA, Curran T. (1994) Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 13:325338.
  • Fukaya M, Yamazaki M, Sakimura K, Watanabe M. (2005) Spatial diversity in gene expression for VDCCgamma subunit family in developing and adult mouse brains. Neurosci Res 53:376383.
  • Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G. (2001) Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 21:58045812.
  • Galanopoulou AS, Buckmaster PS, Staley KJ, Moshe SL, Perucca E, Engel J Jr, Loscher W, Noebels JL, Pitkanen A, Stables J, White HS, O’Brien TJ, Simonato M. (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571582.
  • Garcia CC, Blair HJ, Seager M, Coulthard A, Tennant S, Buddles M, Curtis A, Goodship JA. (2004) Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy. J Med Genet 41:183186.
  • Garske GE, Palmer GC, Napier JJ, Griffith RC, Freedman LR, Harris EW, Ray R, McCreedy SA, Blosser JC, Woodhead JH, White S, Swinyard EA. (1991) Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 9:161174.
  • Gehlert DR. (1994) Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci 55:551562.
  • Gottsch ML, Zeng H, Hohmann JG, Weinshenker D, Clifton DK, Steiner RA. (2005) Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). Mol Cell Biol 25:48044811.
  • Goussakov IV, Fink K, Elger CE, Beck H. (2000) Metaplasticity of mossy fiber synaptic transmission involves altered release probability. J Neurosci 20:34343441.
  • Govindaiah G, Cox CL. (2006) Metabotropic glutamate receptors differentially regulate GABAergic inhibition in thalamus. J Neurosci 26:1344313453.
  • Gulyas AI, Hajos N, Katona I, Freund TF. (2003) Interneurons are the local targets of hippocampal inhibitory cells which project to the medial septum. Eur J Neurosci 17:18611872.
  • Guo H, Castro PA, Palmiter RD, Baraban SC. (2002) Y5 receptors mediate neuropeptide Y actions at excitatory synapses in area CA3 of the mouse hippocampus. J Neurophysiol 87:558566.
  • Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. (2011) Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52:13311340.
  • Heine M. (2012) Surface traffic in synaptic membranes. Adv Exp Med Biol 970:197219.
  • Heinrich C, Lahteinen S, Suzuki F, Anne-Marie L, Huber S, Haussler U, Haas C, Larmet Y, Castren E, Depaulis A. (2011) Increase in BDNF-mediated TrkB signaling promotes epileptogenesis in a mouse model of mesial temporal lobe epilepsy. Neurobiol Dis 42:3547.
  • Hilfiker S, Benfenati F, Doussau F, Nairn AC, Czernik AJ, Augustine GJ, Greengard P. (2005) Structural domains involved in the regulation of transmitter release by synapsins. J Neurosci 25:26582669.
  • Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. (1990) Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 9:24592464.
  • Horak M, Wenthold RJ. (2009) Different roles of C-terminal cassettes in the trafficking of full-length NR1 subunits to the cell surface. J Biol Chem 284:96839691.
  • Hughes SW, Cope DW, Blethyn KL, Crunelli V. (2002) Cellular mechanisms of the slow (<1 Hz) oscillation in thalamocortical neurons in vitro. Neuron 33:947958.
  • Humpel C, Wetmore C, Olson L. (1993) Regulation of brain-derived neurotrophic factor messenger RNA and protein at the cellular level in pentylenetetrazol-induced epileptic seizures. Neuroscience 53:909918.
  • Inamura M, Itakura M, Okamoto H, Hoka S, Mizoguchi A, Fukazawa Y, Shigemoto R, Yamamori S, Takahashi M. (2006) Differential localization and regulation of stargazin-like protein, gamma-8 and stargazin in the plasma membrane of hippocampal and cortical neurons. Neurosci Res 55:4553.
  • Isackson PJ, Huntsman MM, Murray KD, Gall CM. (1991) BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF. Neuron 6:937948.
  • Jackson AC, Nicoll RA. (2011) The expanding social network of ionotropic glutamate receptors: TARPs and other transmembrane auxiliary subunits. Neuron 70:178199.
  • Jane DE, Lodge D, Collingridge GL. (2009) Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 56:90113.
  • Janz R, Sudhof TC. (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94:12791290.
  • Janz R, Goda Y, Geppert M, Missler M, Sudhof TC. (1999) SV2A and SV2B function as redundant Ca2 +  regulators in neurotransmitter release. Neuron 24:10031016.
  • Jovanovska V, Krishnasamy N, Powell K, Bland R, During MJ, O’Brien TJ, Morris MJ. (2011) Gene therapy for idiopathic generalised epilepsy: viral-vector mediated NPY overexpression in ventrolateral thalamus suppresses absence-like seizures in a genetic rat mode. Australian and New Zealand Association of Neurologists Annual Scientific Meeting, Hobart, Australia.
  • Kalashnikova E, Lorca RA, Kaur I, Barisone GA, Li B, Ishimaru T, Trimmer JS, Mohapatra DP, Diaz E. (2010) SynDIG1: an activity-regulated, AMPA- receptor-interacting transmembrane protein that regulates excitatory synapse development. Neuron 65:8093.
  • Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. (2009) Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 50:387397.
  • Kammermeier PJ, Worley PF. (2007) Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proc Natl Acad Sci U S A 104:60556060.
  • Kaplan DR, Miller FD. (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381391.
  • Kato A, Ozawa F, Saitoh Y, Hirai K, Inokuchi K. (1997) vesl, a gene encoding VASP/Ena family related protein, is upregulated during seizure, long-term potentiation and synaptogenesis. FEBS Lett 412:183189.
  • Kato AS, Gill MB, Ho MT, Yu H, Tu Y, Siuda ER, Wang H, Qian YW, Nisenbaum ES, Tomita S, Bredt DS. (2010) Hippocampal AMPA receptor gating controlled by both TARP and cornichon proteins. Neuron 68:10821096.
  • Kennard JT, Barmanray R, Sampurno S, Ozturk E, Reid CA, Paradiso L, D’Abaco GM, Kaye AH, Foote SJ, O’Brien TJ, Powell KL. (2011) Stargazin and AMPA receptor membrane expression is increased in the somatosensory cortex of genetic absence epilepsy rats from Strasbourg. Neurobiol Dis 42:4854.
  • Kielland A, Erisir A, Walaas SI, Heggelund P. (2006) Synapsin utilization differs among functional classes of synapses on thalamocortical cells. J Neurosci 26:57865793.
  • Kim JH, Huganir RL. (1999) Organization and regulation of proteins at synapses. Curr Opin Cell Biol 11:248254.
  • Klugmann M, Symes CW, Leichtlein CB, Klaussner BK, Dunning J, Fong D, Young D, During MJ. (2005) AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol Cell Neurosci 28:347360.
  • Kobayashi M, Buckmaster PS. (2003) Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. J Neurosci 23:24402452.
  • Koch D, Spiwoks-Becker I, Sabanov V, Sinning A, Dugladze T, Stellmacher A, Ahuja R, Grimm J, Schuler S, Muller A, Angenstein F, Ahmed T, Diesler A, Moser M, Tom Dieck S, Spessert R, Boeckers TM, Fassler R, Hubner CA, Balschun D, Gloveli T, Kessels MM, Qualmann B. (2011) Proper synaptic vesicle formation and neuronal network activity critically rely on syndapin I. EMBO J 30:49554969.
  • Kofler N, Kirchmair E, Schwarzer C, Sperk G. (1997) Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats. Neurosci Lett 230:129132.
  • Kogo N, Dalezios Y, Capogna M, Ferraguti F, Shigemoto R, Somogyi P. (2004) Depression of GABAergic input to identified hippocampal neurons by group III metabotropic glutamate receptors in the rat. Eur J Neurosci 19:27272740.
  • Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. (2012) Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 125:815.
  • Krestel HE, Shimshek DR, Jensen V, Nevian T, Kim J, Geng Y, Bast T, Depaulis A, Schonig K, Schwenk F, Bujard H, Hvalby O, Sprengel R, Seeburg PH. (2004) A genetic switch for epilepsy in adult mice. J Neurosci 24:1056810578.
  • Lakhan R, Kalita J, Misra UK, Kumari R, Mittal B. (2010) Association of intronic polymorphism rs3773364 A>G in synapsin-2 gene with idiopathic epilepsy. Synapse 64:403408.
  • Letts VA, Felix R, Biddlecome GH, Arikkath J, Mahaffey CL, Valenzuela A, Bartlett FS II, Mori Y, Campbell KP, Frankel WN. (1998) The mouse stargazer gene encodes a neuronal Ca2 + -channel gamma subunit. Nat Genet 19:340347.
  • Liang F, Le LD, Jones EG. (1998) Reciprocal up- and down-regulation of BDNF mRNA in tetanus toxin-induced epileptic focus and inhibitory surround in cerebral cortex. Cereb Cortex 8:481491.
  • Lindner D, Stichel J, Beck-Sickinger AG. (2008) Molecular recognition of the NPY hormone family by their receptors. Nutrition 24:907917.
  • Lo BW, Kyu HH, Jichici D, Upton AM, Akl EA, Meade MO. (2011) Meta-analysis of randomized trials on first line and adjunctive levetiracetam. Can J Neurol Sci 38:475486.
  • Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:98619866.
  • Marksteiner J, Sperk G, Maas D. (1989) Differential increases in brain levels of neuropeptide Y and vasoactive intestinal polypeptide after kainic acid-induced seizures in the rat. Naunyn Schmiedebergs Arch Pharmacol 339:173177.
  • Marsh DJ, Baraban SC, Hollopeter G, Palmiter RD. (1999) Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc Natl Acad Sci U S A 96:1351813523.
  • Matagne A, Margineanu DG, Potschka H, Loscher W, Michel P, Kenda B, Klitgaard H. (2009) Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol 614:3037.
  • Mathern GW, Pretorius JK, Leite JP, Kornblum HI, Mendoza D, Lozada A, Bertram EH III. (1998) Hippocampal AMPA and NMDA mRNA levels and subunit immunoreactivity in human temporal lobe epilepsy patients and a rodent model of chronic mesial limbic epilepsy. Epilepsy Res 32:154171.
  • Mazarati A, Lu X. (2005) Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides 39:277280.
  • Mazarati AM, Hohmann JG, Bacon A, Liu H, Sankar R, Steiner RA, Wynick D, Wasterlain CG. (2000) Modulation of hippocampal excitability and seizures by galanin. J Neurosci 20:62766281.
  • Mazarati A, Lu X, Kilk K, Langel U, Wasterlain C, Bartfai T. (2004) Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 19:32353244.
  • Mazarati A, Lundstrom L, Sollenberg U, Shin D, Langel U, Sankar R. (2006) Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype-selective agonists and the role of G-protein-mediated signaling. J Pharmacol Exp Ther 318:700708.
  • McColl CD, Jacoby AS, Shine J, Iismaa TP, Bekkers JM. (2006) Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal EEGs and altered inhibition in the hippocampus. Neuropharmacology 50:209218.
  • McNamara JO, Huang YZ, Leonard AS. (2006) Molecular signaling mechanisms underlying epileptogenesis. Sci STKE 2006:re12.
  • Meeren HK, Pijn JP, Van Luijtelaar EL, Coenen AM, Lopes da Silva FH. (2002) Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J Neurosci 22:14801495.
  • Meldrum BS, Rogawski MA. (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4:1861.
  • Merten N, Beck-Sickinger AG. (2006) Molecular ligand-receptor interaction of the NPY/PP peptide family. EXS 95:3562.
  • Messa M, Congia S, Defranchi E, Valtorta F, Fassio A, Onofri F, Benfenati F. (2010) Tyrosine phosphorylation of synapsin I by Src regulates synaptic-vesicle trafficking. J Cell Sci 123:22562265.
  • Messaoudi E, Bardsen K, Srebro B, Bramham CR. (1998) Acute intrahippocampal infusion of BDNF induces lasting potentiation of synaptic transmission in the rat dentate gyrus. J Neurophysiol 79:496499.
  • Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I. (2007) Clinical potential of neuropeptide Y receptor ligands in the treatment of epilepsy. Curr Top Med Chem 7:16601674.
  • Mineff EM, Weinberg RJ. (2000) Differential synaptic distribution of AMPA receptor subunits in the ventral posterior and reticular thalamic nuclei of the rat. Neuroscience 101:969982.
  • Mitsukawa K, Lu X, Bartfai T. (2010) Galanin, galanin receptors, and drug targets. EXS 102:723.
  • Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529540.
  • Morris MJ, Gannan E, Stroud LM, Beck-Sickinger AG, O’Brien TJ. (2007) Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors. Eur J Neurosci 25:11361143.
  • Mosbacher J, Schoepfer R, Monyer H, Burnashev N, Seeburg PH, Ruppersberg JP. (1994) A molecular determinant for submillisecond desensitization in glutamate receptors. Science 266:10591062.
  • Moschovos C, Kostopoulos G, Papatheodoropoulos C. (2012) Endogenous adenosine induces NMDA receptor-independent persistent epileptiform discharges in dorsal and ventral hippocampus via activation of A2 receptors. Epilepsy Res 100:157167.
  • Ngomba RT, Santolini I, Biagioni F, Molinaro G, Simonyi A, van Rijn CM, D’Amore V, Mastroiacovo F, Olivieri G, Gradini R, Ferraguti F, Battaglia G, Bruno V, Puliti A, van Luijtelaar G, Nicoletti F. (2011) Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology 60:12811291.
  • Nibuya M, Morinobu S, Duman RS. (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:75397547.
  • Noe F, Pool AH, Nissinen J, Gobbi M, Bland R, Rizzi M, Balducci C, Ferraguti F, Sperk G, During MJ, Pitkanen A, Vezzani A. (2008) Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131:15061515.
  • Noe F, Frasca A, Balducci C, Carli M, Sperk G, Ferraguti F, Pitkanen A, Bland R, Fitzsimons H, During M, Vezzani A. (2009) Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics 6:300306.
  • Norris SK, King AE. (1997) Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Neuropharmacology 36:951959.
  • Obay BD, Tasdemir E, Tumer C, Bilgin HM, Sermet A. (2007) Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats. Peptides 28:12141219.
  • Ortiz AA, Milardo LF, DeCarr LB, Buckholz TM, Mays MR, Claus TH, Livingston JN, Mahle CD, Lumb KJ. (2007) A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J Pharmacol Exp Ther 323:692700.
  • Palmer GC, Stagnitto ML, Ordy JM, Griffith RC, Napier JJ, Gentile RJ, Woodhead JH, White HS, Swinyard EA. (1991) Preclinical profile of stereoisomers of the anticonvulsant remacemide in mice. Epilepsy Res 8:3648.
  • Patel YC. (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157198.
  • Pedrazzini T, Pralong F, Grouzmann E. (2003) Neuropeptide Y: the universal soldier. Cell Mol Life Sci 60:350377.
  • Pellock JM. (1999) Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 21:225239.
  • Perez-Otano I, Ehlers MD. (2005) Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci 28:229238.
  • Portelli J, Michotte Y, Smolders I. (2012) Ghrelin: an emerging new anticonvulsant neuropeptide. Epilepsia 53:585595.
  • Potschka H, Krupp E, Ebert U, Gumbel C, Leichtlein C, Lorch B, Pickert A, Kramps S, Young K, Grune U, Keller A, Welschof M, Vogt G, Xiao B, Worley PF, Loscher W, Hiemisch H. (2002) Kindling-induced overexpression of Homer 1A and its functional implications for epileptogenesis. Eur J Neurosci 16:21572165.
  • Poulsen FR, Jahnsen H, Blaabjerg M, Zimmer J. (2002) Pilocarpine-induced seizure-like activity with increased BNDF and neuropeptide Y expression in organotypic hippocampal slice cultures. Brain Res 950:103118.
  • Powell KL, Kyi M, Reid CA, Paradiso L, D’Abaco GM, Kaye AH, Foote SJ, O’Brien TJ. (2008) Genetic absence epilepsy rats from Strasbourg have increased corticothalamic expression of stargazin. Neurobiol Dis 31:261265.
  • Priel A, Kolleker A, Ayalon G, Gillor M, Osten P, Stern-Bach Y. (2005) Stargazin reduces desensitization and slows deactivation of the AMPA-type glutamate receptors. J Neurosci 25:26822686.
  • Prince HK, Conn PJ, Blackstone CD, Huganir RL, Levey AI. (1995) Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. J Neurochem 64:462465.
  • Prince HC, Tzingounis AV, Levey AI, Conn PJ. (2000) Functional downregulation of GluR2 in piriform cortex of kindled animals. Synapse 38:489498.
  • Qualmann B, Kelly RB. (2000) Syndapin isoforms participate in receptor-mediated endocytosis and actin organization. J Cell Biol 148:10471062.
  • Qualmann B, Roos J, DiGregorio PJ, Kelly RB. (1999) Syndapin I, a synaptic dynamin-binding protein that associates with the neural Wiskott-Aldrich syndrome protein. Mol Biol Cell 10:501513.
  • Raimondi A, Ferguson SM, Lou X, Armbruster M, Paradise S, Giovedi S, Messa M, Kono N, Takasaki J, Cappello V, O’Toole E, Ryan TA, De Camilli P. (2011) Overlapping role of dynamin isoforms in synaptic vesicle endocytosis. Neuron 70:11001114.
  • Rajasekaran K, Todorovic M, Kapur J. (2012) Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol 72:91102.
  • Ramachandran R. (2011) Vesicle scission: dynamin. Semin Cell Dev Biol 22:1017.
  • Reibel S, Nadi S, Benmaamar R, Larmet Y, Carnahan J, Marescaux C, Depaulis A. (2001) Neuropeptide Y and epilepsy: varying effects according to seizure type and receptor activation. Peptides 22:529539.
  • Richichi C, Lin EJ, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A. (2004) Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24:30513059.
  • Rodriguez-Moreno A, Lerma J. (1998) Kainate receptor modulation of GABA release involves a metabotropic function. Neuron 20:12111218.
  • Rogawski MA. (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11:5663.
  • Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hokfelt T, Wasterlain C, Bartfai T, Langel U. (2002) Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A 99:71367141.
  • Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. (1992) Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 32:386392.
  • Sakagami Y, Yamamoto K, Sugiura S, Inokuchi K, Hayashi T, Kato N. (2005) Essential roles of Homer-1a in homeostatic regulation of pyramidal cell excitability: a possible link to clinical benefits of electroconvulsive shock. Eur J Neurosci 21:32293239.
  • Salt TE, Eaton SA. (1995) Modulation of sensory neurone excitatory and inhibitory responses in the ventrobasal thalamus by activation of metabotropic excitatory amino acid receptors. Neuropharmacology 34:10431051.
  • Salt TE, Turner JP. (1998) Modulation of sensory inhibition in the ventrobasal thalamus via activation of group II metabotropic glutamate receptors by 2R,4R-aminopyrrolidine-2,4-dicarboxylate. Exp Brain Res 121:181185.
  • Sanchez RM, Koh S, Rio C, Wang C, Lamperti ED, Sharma D, Corfas G, Jensen FE. (2001) Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. J Neurosci 21:81548163.
  • Schmidt-Kastner R, Humpel C, Wetmore C, Olson L. (1996) Cellular hybridization for BDNF, trkB, and NGF mRNAs and BDNF-immunoreactivity in rat forebrain after pilocarpine-induced status epilepticus. Exp Brain Res 107:331347.
  • Schneider BM, Dodman NH, Faissler D, Ogata N. (2009) Clinical use of an herbal-derived compound (Huperzine A) to treat putative complex partial seizures in a dog. Epilepsy Behav 15:529534.
  • Schwenk J, Harmel N, Zolles G, Bildl W, Kulik A, Heimrich B, Chisaka O, Jonas P, Schulte U, Fakler B, Klocker N. (2009) Functional proteomics identify cornichon proteins as auxiliary subunits of AMPA receptors. Science 323:13131319.
  • Seeburg PH, Hartner J. (2003) Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr Opin Neurobiol 13:279283.
  • Selcher JC, Xu W, Hanson JE, Malenka RC, Madison DV. (2012) Glutamate receptor subunit GluA1 is necessary for long-term potentiation and synapse unsilencing, but not long-term depression in mouse hippocampus. Brain Res 1435:814.
  • Sheldon AL, Robinson MB. (2007) The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 51:333355.
  • Shin DM, Dehoff M, Luo X, Kang SH, Tu J, Nayak SK, Ross EM, Worley PF, Muallem S. (2003) Homer 2 tunes G protein-coupled receptors stimulus intensity by regulating RGS proteins and PLCbeta GAP activities. J Cell Biol 162:293303.
  • Sofia RD. (1994) Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 36:677678.
  • Sommer B, Kohler M, Sprengel R, Seeburg PH. (1991) RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 67:1119.
  • Sorensen AT, Nikitidou L, Ledri M, Lin EJ, During MJ, Kanter-Schlifke I, Kokaia M. (2009) Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp Neurol 215:328333.
  • Srinivasan J, Richens A, Davies JA. (1997) The effect of losigamone (AO-33) on electrical activity and excitatory amino acid release in mouse cortical slices. Br J Pharmacol 122:14901494.
  • Srivastava S, Osten P, Vilim FS, Khatri L, Inman G, States B, Daly C, DeSouza S, Abagyan R, Valtschanoff JG, Weinberg RJ, Ziff EB. (1998) Novel anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor-binding protein ABP. Neuron 21:581591.
  • Stansfield KH, Pilsner JR, Lu Q, Wright RO, Guilarte TR. (2012) Dysregulation of BDNF-TrkB signaling in developing hippocampal neurons by Pb(2 + ): implications for an environmental basis of neurodevelopmental disorders. Toxicol Sci 127:277295.
  • Streit AK, Derst C, Wegner S, Heinemann U, Zahn RK, Decher N. (2011) RNA editing of Kv1.1 channels may account for reduced ictogenic potential of 4-aminopyridine in chronic epileptic rats. Epilepsia 52:645648.
  • Stroud LM, O’Brien TJ, Jupp B, Wallengren C, Morris MJ. (2005) Neuropeptide Y suppresses absence seizures in a genetic rat model. Brain Res 1033:151156.
  • Subramaniam S, Donevan SD, Rogawski MA. (1996) Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther 276:161168.
  • Tanaka H, Grooms SY, Bennett MV, Zukin RS. (2000) The AMPAR subunit GluR2: still front and center-stage. Brain Res 886:190207.
  • Tomioka R, Okamoto K, Furuta T, Fujiyama F, Iwasato T, Yanagawa Y, Obata K, Kaneko T, Tamamaki N. (2005) Demonstration of long-range GABAergic connections distributed throughout the mouse neocortex. Eur J Neurosci 21:15871600.
  • Tomita S, Chen L, Kawasaki Y, Petralia RS, Wenthold RJ, Nicoll RA, Bredt DS. (2003) Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins. J Cell Biol 161:805816.
  • Tomita S, Fukata M, Nicoll RA, Bredt DS. (2004) Dynamic interaction of stargazin-like TARPs with cycling AMPA receptors at synapses. Science 303:15081511.
  • Tomita S, Stein V, Stocker TJ, Nicoll RA, Bredt DS. (2005) Bidirectional synaptic plasticity regulated by phosphorylation of stargazin-like TARPs. Neuron 45:269277.
  • Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R. (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405496.
  • Tu B, Timofeeva O, Jiao Y, Nadler JV. (2005) Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain. J Neurosci 25:17181729.
  • Turnbull J, Lohi H, Kearney JA, Rouleau GA, Delgado-Escueta AV, Meisler MH, Cossette P, Minassian BA. (2005) Sacred disease secrets revealed: the genetics of human epilepsy. Hum Mol Genet 14(No. 2):24912500.
  • Turner JP, Salt TE. (1998) Characterization of sensory and corticothalamic excitatory inputs to rat thalamocortical neurones in vitro. J Physiol 510(Pt 3):829843.
  • Turner JP, Salt TE. (2000) Synaptic activation of the group I metabotropic glutamate receptor mGlu1 on the thalamocortical neurons of the rat dorsal lateral geniculate nucleus in vitro. Neuroscience 100:493505.
  • Turner JP, Salt TE. (2003) Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro. Neuroscience 122:459469.
  • Upreti C, Otero R, Partida C, Skinner F, Thakker R, Pacheco LF, Zhou ZY, Maglakelidze G, Veliskova J, Velisek L, Romanovicz D, Jones T, Stanton PK, Garrido-Sanabria ER. (2012) Altered neurotransmitter release, vesicle recycling and presynaptic structure in the pilocarpine model of temporal lobe epilepsy. Brain 135:869885.
  • van Raay L, Jovanovska V, Morris MJ, O’Brien TJ. (2012) Focal administration of neuropeptide Y into the S2 somatosensory cortex maximally suppresses absence seizures in a genetic rat model. Epilepsia 53:477484.
  • van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. (2009) Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 50:422433.
  • Ved HS, Koenig ML, Dave JR, Doctor BP. (1997) Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 8:963968.
  • Vezzani A, Schwarzer C, Lothman EW, Williamson J, Sperk G. (1996) Functional changes in somatostatin and neuropeptide Y containing neurons in the rat hippocampus in chronic models of limbic seizures. Epilepsy Res 26:267279.
  • Vezzani A, Sperk G, Colmers WF. (1999) Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 22:2530.
  • Vezzani A, Moneta D, Mule F, Ravizza T, Gobbi M, French-Mullen J. (2000) Plastic changes in neuropeptide Y receptor subtypes in experimental models of limbic seizures. Epilepsia 41(Suppl. 6):S115S121.
  • Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J. (2008) Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol 286:7587.
  • Vogl C, Mochida S, Wolff C, Whalley BJ, Stephens GJ. (2012) The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2 +  channels through an intracellular pathway. Mol Pharmacol 82:199208.
  • Vollmar W, Gloger J, Berger E, Kortenbruck G, Kohling R, Speckmann EJ, Musshoff U. (2004) RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. Neurobiol Dis 15:371379.
  • von Engelhardt J, Mack V, Sprengel R, Kavenstock N, Li KW, Stern-Bach Y, Smit AB, Seeburg PH, Monyer H. (2010) CKAMP44: a brain-specific protein attenuating short-term synaptic plasticity in the dentate gyrus. Science 327:15181522.
  • von Rosenstiel P. (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4:8487.
  • Walther C, Morl K, Beck-Sickinger AG. (2011) Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J Pept Sci 17:233246.
  • Wan QF, Zhou ZY, Thakur P, Vila A, Sherry DM, Janz R, Heidelberger R. (2010) SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 66:884895.
  • Wang FJ, Li CM, Hou XH, Wang XR, Zhang LM. (2011) Selective upregulation of brain-derived neurotrophic factor (BDNF) transcripts and BDNF direct induction of activity independent N-methyl-D-aspartate currents in temporal lobe epilepsy patients with hippocampal sclerosis. J Int Med Res 39:13581368.
  • Wesnes KA, Edgar C, Dean AD, Wroe SJ. (2009) The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav 14:522528.
  • Wetmore C, Ernfors P, Persson H, Olson L. (1990) Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp Neurol 109:141152.
  • White HS, Scholl EA, Klein BD, Flynn SP, Pruess TH, Green BR, Zhang L, Bulaj G. (2009) Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models. Neurotherapeutics 6:372380.
  • Wiater MF, Mukherjee S, Li AJ, Dinh TT, Rooney EM, Simasko SM, Ritter S. (2011) Circadian integration of sleep-wake and feeding requires NPY receptor-expressing neurons in the mediobasal hypothalamus. Am J Physiol Regul Integr Comp Physiol 301:R1569R1583.
  • Widdowson PS. (1993) Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain. Brain Res 631:2738.
  • Wu JT, Kral JG. (2004) Ghrelin: integrative neuroendocrine peptide in health and disease. Ann Surg 239:464474.
  • Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D, Mathe AA. (2011) Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets 15:13171331.
  • Xia J, Zhang X, Staudinger J, Huganir RL. (1999) Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron 22:179187.
  • Yao J, Bajjalieh SM. (2008) Synaptic vesicle protein 2 binds adenine nucleotides. J Biol Chem 283:2062820634.
  • Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM. (2010) Cotrafficking of SV2 and synaptotagmin at the synapse. J Neurosci 30:55695578.
  • Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. (1990) Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 9:35453550.
  • Zhang YH, Zhao XY, Chen XQ, Wang Y, Yang HH, Hu GY. (2002) Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex. Neurosci Lett 319:107110.
  • Ziff EB. (2007) TARPs and the AMPA receptor trafficking paradox. Neuron 53:627633.
  • Zini S, Roisin MP, Langel U, Bartfai T, Ben-Ari Y. (1993) Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur J Pharmacol 245:17.